The suppression of the pituitary-gonadal axis by the administration of gonadotrophin-releasing hormone agonists (GnRH-a) is used occasionally as an adjunct therapy with gonadotrophins for ovulation induction in women with polycystic ovarian syndrome (PCOS). A number of recent clinical studies have suggested that women with polycystic ovaries (PCO) may have disturbances of normal growth hormone (GH) kinetics and alterations in the GH/insulin-like growth factor (IGF)-I system. The purpose of this study was to determine the effect of GnRH-a administration on GHreleasing hormone (GHRH)-stimulated GH release in women with PCOS. Eight women with PCO and six control women were studied before and after 2 months of treatment with the long acting GnRH-a triptoreline (3.75 mg monthly injections). GHRH was given as a single i.v. injection and blood samples for GH measurements were obtained at -15, 0, 30, 60, 90 and 120 min. The GH responses were expressed as the area under the curve (AUC) or the differences from the basal value (∆ max ). The GH response to GHRH (mean ⍨ SEM) was lower in women with PCO (AUC 114.9 ⍨ 43.1 versus 206.2 ⍨ 28.7 ng/ml/120 min, P < 0.05 and ∆ max 31.6 ⍨ 8.2 versus 49.4 ⍨ 5.8 ng/ml, P < 0.05). After treatment with the GnRH-a, the GH response to GHRH was significantly smaller than before treatment in both groups (PCO AUC 34.6 ⍨ 9.0 ng/ml/120 min and ∆ max 12.4 ⍨ 3.1 ng/ml; controls AUC 148.8 ⍨ 28.4 ng/ml/120 min and ∆ max 31.2 ⍨ 6.1 ng/ml), but the PCO group had a significantly smaller response. These data demonstrate that women with PCO have a reduced GH response to GHRH compared with normal controls and that GnRH-a administration causes a further GH reduction in both groups. Women with PCO have a greater suppression of GH response to GHRH during treatment with GnRH-a. This suggests that a different level of sensitivity in the somatotrophic axis exists in PCOS.
Introduction
The administration of gonadotrophin-releasing hormone agonists (GnRH-a) suppresses luteinizing hormone (LH) and follicle
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© European Society for Human Reproduction and Embryology stimulating hormone (FSH) release and consequently ovarian oestradiol production. The mechanism involves downregulation of pituitary gonadotrophin receptors, although a post-receptor effect is possible. These effects of GnRH-a are used in the treatment of various gynaecological and endocrine disorders, such as uterine leiomyomata, endometriosis and precocious puberty (Forti, 1988) . After the original report by Fleming et al. (1985) , GnRH-a have been used occasionally as an adjunct therapy with human menopausal gonadotrophins for ovulation induction in women with polycystic ovarian syndrome (PCOS; Artini et al., 1996) . Apart from the suppression of the pituitary-gonadal axis, GnRH-a also affect some other aspects of pituitary function. For instance, they suppress basal growth hormone (GH) release and that stimulated by GH-releasing hormone (GHRH), and affect insulin-like growth factor (IGF)-I concentrations in adult pre-menopausal women (Friedman et al., 1990; Word et al., 1990) , as well as decrease serum prolactin (PRL) concentrations in women with hyperprolactinaemia (Golan et al., 1989) ; however they do not alter the hypothalamic-pituitary-adrenal axis (Wilson et al., 1993) .
Women with polycystic ovaries (PCO) have a disturbance of normal GH kinetics. Serum GH baseline concentrations in women with PCO have been variously described as low, normal or elevated (Urdl, 1988; Katz et al., 1993) , while the diurnal GH secretion was found to be impaired (Kazer et al., 1990; Prelevic et al., 1992) . It has been shown that women with PCO have a relative deficiency (Acar and Kadanali, 1993) or reduction (Lee et al., 1993) in GH reserve after oral L-dopa stimulation. The GH concentrations after GHRH administration were found to be impaired in women with PCO (Lanzone et al., 1995; Piaditis et al., 1995; Micic et al., 1996) . A number of recent clinical studies have also suggested alterations in the GH/IGF-I system in women with PCO. These studies have reported that women with PCO have higher than normal adult concentrations of IGF-I (Iwashita et al., 1990; Lee et al., 1993; Kaltsas et al., 1996) . However, little is known about the effect of GnRH-a on GH release in women with PCO.
The purpose of this study was to evaluate the effect of GnRH-a administration on GHRH-stimulated GH release in women with PCO. The results may provide further insight into the pathophysiology of PCO and may also be of interest in clinical terms, because both GnRH-a and GH are used occasionally in combination with human gonadotrophins for ovulation induction in women with PCOS.
Materials and methods

Patients
Eight women with PCO, aged 20-28 years, were studied. The clinical diagnosis of PCO was based on the presence of oligomenorrhoea of peri-menarcheal onset, and hirsutism. All women had hyperandrogenaemia and the typical ultrasound appearance of PCO (ജ10 cysts 2-8 mm in diameter associated with an increase in ovarian stroma; Adams et al., 1986) . None of the women had used any hormonal or other medication during the 3 months before the commencement of the study.
Six healthy, normally menstruating women aged 21-29 years were used as controls. They were studied during the early follicular phase, whereas the women with PCO were studied on day 4 following a spontaneous or a progesterone-induced menstrual bleed. The study was approved by the local ethical committee, and informed consent was obtained from all subjects.
Blood samples (in relation to a bolus i.v. injection of GHRH, time 0) were obtained at -15, 0, 30, 60, 90 and 120 min for the measurement of GH. The dose of GHRH was 2 µg/kg [GHRH (1-29) NH 2 Geref; Serono, Milan, Italy]. This dose was chosen because it stimulated the maximal GH response in the majority of normal adults (Boissel et al., 1986) . In all blood samples taken at -15 and 0 min, basal FSH, LH, oestradiol, free testosterone, androstenedione, GH, IGF-I, IGF binding protein 3 (IGFBP-3), IGFBP-1, insulin, glucose and free fatty acid concentrations were measured. Immediately after the GHRH test, all women received two doses of 3.75 mg each, 28 days apart, of the long-acting GnRH-a D-Trp-6-LHRH (Arvecap; Ipsen Biotech, Paris, France). The GHRH test was repeated after the end of the 2 months of treatment with the GnRH-a. All blood samples were centrifuged immediately at 1000 g for 10 min at 4°C. Supernatant serum was aspirated, aliquoted and stored at -20°C until assayed.
Hormone assays
IGF-I concentrations were measured by a radioimmunoassay following acid-ethanol extraction. Kits were purchased from Nichols Institute (San Juan Capistrano, CA, USA). The intra-and interassay coefficients of variation (CV) were 4.4 and 5.8% respectively, and the results were expressed as ng/ml. IGFBP-3 measurements were performed by a radioimmunoassay using a specific competitive protein-binding radioimmunoassay. Kits were purchased from Nichols Institute. The intra-and interassay CV were 5.2 and 6.1% respectively, and the results were expressed as mg/ml. Serum concentrations of IGFBP-1 were measured by a radioimmunoassay. Kits were purchased from Nichols Institute. The intra-and interassay CV were 6.2 and 9.8% respectively, and the results were expressed as ng/ml. Serum FSH and LH concentrations were measured using immunometric assays based on enhanced luminescence (Amerlite FSH assay and Amerlite LH-30 assay respectively). Kits were purchased from Amersham International Plc (Amersham, UK). Serum oestradiol concentrations were measured using a competitive immunoassay (Amerlite Estradiol-60 assay) based on enhanced luminescence. Kits were purchased from Amersham. The lower limits of detection for FSH, LH and oestradiol were 0.5 mIU/l, 0.12 mIU/l and 50 pg/ml respectively, while interassay and intra-assay CV were 7.5 and 5.9, 9.0 and 6.8, and 9.3 and 8.5% respectively. Insulin was measured by a radioimmunoassay using a Bio-International Kit from CIS (Paris, France). The results were expressed as µIU/ml. GH was measured by an immunoradiometric assay using a Biomedica Kit from Sorin (Saluggia, Italy). The results were expressed as ng/ml. Free testosterone was measured by employing a radioimmunoassay using a Coat-A-Count Kit (Diagnostic Products Corporation, Los Angeles, CA, USA). The results were expressed as pg/ml. Androstenedione was measured by a radioimmunoassay using a RADIM Kit (Pomezia, Italy). The results were expressed as ng/ml. The lower limits of detection for insulin, GH, free testosterone and androstenedione were 3.6 µIU/ml, 0.15 ng/ml, 0.15 pg/ml and 0.1 ng/ml respectively, while interassay and intra-assay CV were 6.9 and 6.4, 7.5 and 6.1, 8.1 and 7.2, and 7.6 and 5.1% respectively. Glucose concentrations were determined by the glucose oxidase technique. An enzymatic method was used to determine serum free fatty acids (Wako Chemicals Gmbh, Neuss, Germany).
Statistical analysis
GH release in response to GHRH administration was estimated by computing the area under the curve (AUC) using the trapezoidal rule. The mean of the concentrations at -15 and 0 min was used as baseline value. The GH peak concentration in response to the stimulus was defined as the highest concentration reached in each individual, and the response was expressed as the difference from the baseline value (∆ max ). Paired and unpaired t-tests were used to compare the results at the beginning and end of the study and between the two groups. Statistical significance was considered to be achieved at P Ͻ 0.05.
Results
Women with PCO had similar ages, body mass indices and basal oestradiol, FSH, glucose and free fatty acid concentrations compared with the control women, but significantly higher basal LH, androstenedione, free testosterone, insulin, IGF-I and IGFBP-3 concentrations and significantly lower IGFBP-1 concentrations (Table I ). Basal GH concentrations were similar in PCO and control women. The administration of GHRH induced a significant increase in GH concentration in both groups of women studied. However, GH response (mean Ϯ SEM) to GHRH was significantly lower in women with PCO than in controls respectively at 30 (31.3 Ϯ 8.1 versus 56.2 Ϯ 6.2 ng/ml, P Ͻ 0.01) and 60 min (30.8 Ϯ 9.2 versus 57.4 Ϯ 9.4 ng/ml, P Ͻ 0.01).
There were also significant differences in ∆ max GH response (PCO 31.6 Ϯ 8.2 versus controls 49.4 Ϯ 5.8 ng/ml, P Ͻ 0.05) and in GH AUC (PCO 114.9 Ϯ 43.1 versus controls 206.2 Ϯ 28.7 ng/ml/120 min, P Ͻ 0.05) (Figure 1) .
The 2 month treatment with GnRH-a significantly reduced FSH, LH, oestradiol, androstenedione and free testosterone concentrations in women with PCO, but did not significantly change insulin, GH, IGF-I, IGFBP-3, IGFBP-1, glucose and free fatty acid concentrations (Table II) . In the controls, GnRH-a administration caused a significant reduction in Figure 1 . Growth hormone (GH) release in response to GHreleasing hormone (GHRH) administration was established as the area under the curve (GH AUC). The GH peak concentration in response to the stimulus was defined as the highest concentration reached in each individual, and the response was expressed as the difference from the baseline value (∆ max GH). ∆ max GH and GH AUC (mean Ϯ SEM) are shown, in response to GHRH, in women with polycystic ovarian syndrome (PCOS) and in controls before gonadotrophin-releasing hormone analogue administration. Table II . Basal hormone, glucose and free fatty acid concentrations before and after 2 months of treatment with a gonadotrophin-releasing hormone analogue in women with polycystic ovarian syndrome
Before
After treatment treatment Follicle stimulating hormone (mIU/ml) 7.5 Ϯ 1.0 1.9 Ϯ 0.8 c Luteinizing hormone (mIU/ml) 17.8 Ϯ 1.3 11.1 Ϯ 1.2 c Oestradiol (pg/ml) 48.6 Ϯ 8.6 18.5 Ϯ 2.7 b Free testosterone (pg/ml) 4.1 Ϯ 0.5 2.3 Ϯ 0.6 b Androstenedione (ng/ml) 4.9 Ϯ 0.4 3.2 Ϯ 0.6 a Growth hormone (ng/ml) 1.9 Ϯ 1.2 1.7 Ϯ 0.9 Insulin-like growth factor-I (ng/ml) 287.1 Ϯ 37.9 258.1 Ϯ 22.8 IGFBP-3 (mg/ml) 3.6 Ϯ 0.3 4.1 Ϯ 0.9 IGFBP-1 (ng/ml) 3. only FSH, LH and oestradiol concentrations (Table III) . After treatment with the GnRH-a both groups showed a significantly lower GH response to GHRH stimulation than before treatment. The reduction was significant at 30 min (10.4 Ϯ 3.5 versus 31.3 Ϯ 8.1 ng/ml, P Ͻ 0.05) in PCO patients and at 30 (35.6 Ϯ 5.7 versus 56.2 Ϯ 6.2 ng/ml, P Ͻ 0.0005), 60 (36.3 Ϯ 7.9 versus 57.4 Ϯ 9.4 ng/ml, P Ͻ 0.005) and 90 min (18.1 Ϯ 6.4 versus 27.8 Ϯ 3.4 ng/ml, P Ͻ 0.05) in controls. GH response to GHRH after treatment with the GnRH-a was significantly lower in PCO patients than in controls at 30 and 60 min (P Ͻ 0.005).
The same was true for ∆ max GH response (12.4 Ϯ 3.1 versus 31.2 Ϯ 6.1 ng/ml, P Ͻ 0.01) and GH AUC (34.6 Ϯ 9.0 versus 148.8 Ϯ 28.4 ng/ml/120 min, P Ͻ 0.0005) (Figure 2 ). The mean (ϮSEM) percentage decrease in GH AUC in response to GHRH after treatment with the GnRH-a was Table III . Basal hormone, glucose and free fatty acid concentrations before and after 2 months of treatment with a gonadotrophin-releasing hormone analogue in control women
After treatment treatment Follicle stimulating hormone (mIU/ml) 6.6 Ϯ 0.8 2.9 Ϯ 0.3 a Luteinizing hormone (mIU/ml) 8.4 Ϯ 0.9 4.9 Ϯ 0.8 a Oestradiol (pg/ml) 54.1 Ϯ 2.1 21.5 Ϯ 0.6 a Free testosterone (pg/ml) 1.9 Ϯ 0.4 1.8 Ϯ 0.2 Androstenedione (ng/ml) 2.1 Ϯ 0.3 1.9 Ϯ 0.3 Growth hormone (ng/ml) 2.4 Ϯ 0.9 1.9 Ϯ 0.2 Insulin-like growth factor-I (ng/ml) 184.3 Ϯ 29.4 181.2 Ϯ 27.1 IGFBP-3 (mg/ml) 1.8 Ϯ 0.2 1.9 Ϯ 0.1 IGFBP-1 (ng/ml) 6.8 Ϯ 0.9 7.4 Ϯ 0.8 Insulin (µIU/ml) 10.1 Ϯ 0.8 8. significantly greater in the PCO group (69.9 Ϯ 5.3%) than in the controls (39.9 Ϯ 4.3%) (P Ͻ 0.005; Figure 3) . Similarly, the percentage GH ∆ max decrease was greater in PCO patients (61.0 Ϯ 6.3%) than in controls (36.8 Ϯ 4.9%) (P Ͻ 0.01; Figure 3 ). IGF-I and insulin concentrations, as well as GH response to GHRH stimulation, showed no significant correlations with body mass index.
Discussion
In the present study we found that GHRH-stimulated GH release was suppressed in women with PCO compared with normally menstruating women. An explanation of this suppression is difficult. However it may be related to the higher IGF-I concentrations in the PCO group because it is known that IGF-I suppresses GH secretion directly at the hypothalamic and the pituitary level and indirectly through stimulation of the hypothalamic production of somatostatin both in vitro and in vivo (Berelowitz et al., 1981; Devesa et al., 1992) . Another possibility is that the hyperinsulinaemia is responsible, because insulin can stimulate IGF-I production (Glass, 1989) , increase somatomedin release from perfused rat liver (Daughaday et al., 1976) and suppress basal and GHRH-stimulated GH secretion from rat anterior pituitary cells in culture (Yamashita and Melmed, 1986) . Hyperandrogenaemia in PCO may also contribute to the suppression of GH release after GHRH administration, because testosterone is known to stimulate somatostatin release (Devesa et al., 1992) . Furthermore, earlier reports have demonstrated that free fatty acids are able to block GH response to a number of stimuli including GHRH (Imaki et al., 1985) . Because our PCO women had free fatty acid concentrations similar to the control group, this mechanism of reduced GH response to GHRH must be excluded. The suppressed GH response to GHRH after GnRH-a administration in our control women is in agreement with the results of a previous study (Word et al., 1990) . Regarding women with PCO, only a baseline investigation of the GH-IGF-I axis has been performed after GnRH-a administration (Hatasaka et al., 1994) . Our study is the first to show that the treatment of women with PCO using a GnRH-a suppresses the GH response to GHRH more than in control women, but the mechanism is unclear. Although treatment with a GnRHa in children with precocious puberty suppresses basal and nocturnal serum GH (DiMartino-Nardi et al., 1991; Sklar et al., 1991) , in the present study neither basal GH nor IGF-I concentrations were affected by the GnRH-a administration. Sex steroids may affect GH secretion at the hypothalamus by modulating the rhythmic GHRH-somatostatin interplay and in particular somatostatin availability (Devesa et al., 1991) . It is possible, therefore, that hypo-oestrogenism induced by GnRHa was responsible for the suppression of GH secretion in response to GHRH in both groups of women in this study. The greater suppression in PCO women could be related to the negative effect of other substances on GH secretion, such as insulin and IGF-I, which remained unaltered in this group after GnRH-a administration. Alternatively, it can be assumed that the high steroid concentrations in women with PCO counterbalance, at least in part, the suppressive action of IGF-I and/or insulin on GH secretion. This is in accordance with the significant decrease in oestradiol, free testosterone and androstenedione concentrations after the 2 month treatment with GnRH-a in this study (Table II) , although at least testosterone is known to stimulate somatostatin and hence GH 25 secretion (Devesa et al., 1992) . The possibility that GnRH-a may exert a direct inhibitory effect on GH secretion from the pituitary cannot be excluded.
The physiological importance of these findings is not clear. The results, however, may suggest a possible involvement of GnRH pathways in the control of GH secretion, but this requires further investigation. From a clinical point of view, our results could be interpreted as indicating that the treatment of PCOS patients with a GnRH-a induces a degree of GH deficiency, hence making it possible that addition of GH to the gonadotrophin regimen may be needed during ovulation induction.
In conclusion, our study demonstrates that in women with PCO, the response of GH to GHRH was reduced significantly when compared with normal controls. The administration of a GnRH-a caused a further reduction in GH response to GHRH without affecting basal GH concentrations. This reduction may be attributed to direct pituitary suppression by the GnRH-a or to diminished endogenous oestrogen secretion, or both. The greater suppression of GH response to GHRH in women with PCOS during treatment with the GnRH-a compared with controls may be attributed to the higher insulin and IGF-I concentrations and suggests that a different level of sensitivity exists in the somatotrophic axis in women with PCO.
